MedPath

重庆申高生化制药股份有限公司

Ownership
-
Established
2000-01-19
Employees
-
Market Cap
-
Website
http://www.cqsgzy.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

27

NMPA:27

Drug Approvals

银黄颗粒

Approval Number
国药准字Z20093408
Approval Date
Mar 12, 2024
NMPA

Paracetamol,Caffeine and Aspirin Powder

Product Name
阿咖酚散
Approval Number
国药准字H50021879
Approval Date
Sep 28, 2020
NMPA

Compound Saccharated Pepsin Granules

Product Name
复方胃蛋白酶颗粒
Approval Number
国药准字H50021717
Approval Date
Sep 28, 2020
NMPA

Compound Paracetamol and Chlorphenamine Tablets for Infant

Product Name
小儿氨酚那敏片
Approval Number
国药准字H50021777
Approval Date
Sep 28, 2020
NMPA

Multienzyme Tablets

Product Name
多酶片
Approval Number
国药准字H50021228
Approval Date
Sep 28, 2020
NMPA

Paracetamol,Caffeine and Aspirin Powder

Product Name
阿咖酚散
Approval Number
国药准字H20067953
Approval Date
Sep 27, 2020
NMPA

Compound Sulfadiazine Tablets

Product Name
复方磺胺嘧啶片
Approval Number
国药准字H50020389
Approval Date
Sep 25, 2020
NMPA

Paracetamol, Aminophenazone Phenacetin,Caffeine and Chlorphenamine Maleate Granules

Product Name
酚氨咖敏颗粒
Approval Number
国药准字H50021932
Approval Date
Sep 25, 2020
NMPA

Compound Paracetamol and Amantadine Hydrochloride Capsules

Product Name
复方氨酚烷胺胶囊
Approval Number
国药准字H50021229
Approval Date
Sep 25, 2020
NMPA

Paracetamol,Caffein,Atificial Cow-bezoar and chlorphenamine Maleate capsules

Product Name
氨咖黄敏胶囊
Approval Number
国药准字H50021716
Approval Date
Sep 25, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.